Journal
JOURNAL OF PERSONALIZED MEDICINE
Volume 12, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/jpm12091415
Keywords
collapsing glomerulopathy; rituximab; relapsing disease; multidrug-resistant disease; kidney biopsy
Ask authors/readers for more resources
This report describes a case of a female patient with idiopathic collapsing glomerulopathy that was resistant to multiple immunosuppressive agents but responded well to rituximab, with complete remission achieved upon relapse. This case highlights the potential role of rituximab in treating multidrug-resistant forms of collapsing glomerulopathy and contributes to the limited data available on its efficacy in this condition.
Collapsing glomerulopathy (CG) or collapsing focal segmental glomerulosclerosis (cFSGS) is an aggressive disease with a high tendency of progression to end-stage renal disease due to common resistance to conventional immunosuppressants. Rituximab (RTX), a monoclonal antibody against CD20 B cells, showed some benefit in the treatment of CG. We are reporting about female patients with an idiopathic form of CG presenting with nephrotic syndrome (NS) and renal insufficiency resistant to several immunosuppressive agents such as steroids (ST), calcineurin inhibitors (CNI), and cyclophosphamide (CYC). This multidrug-resistant disease responded to RTX with complete remission. Forty-four months after initial RTX administration, a relapse of CG with severe NS and acute renal insufficiency occurred. Repeated application of RTX led to complete remission again. To the best of our knowledge, we are reporting the first case of the relapsing multidrug-resistant form of CG, which responded to RTX. Current data about the treatment of CG with RTX is lacking and is based on rare case reports and small case series. Thus, our report can contribute to determining the role of RTX in the treatment of CG.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available